Literature DB >> 32748635

IL-6 and Soluble Receptors in Overweight and Obese African American Women With and Without Breast Cancer.

K A Griffith1,2, A S Ryan2,3.   

Abstract

Interleukin 6 (IL-6) and its receptors are expressed in approximately half of breast cancer (BC) tissues, and high serum IL-6 levels are associated with poor prognosis. African American (AA) patients with BC have higher serum IL-6 levels compared to Caucasians, suggesting additional risk of disease-related complications in AAs. The purpose of this study was to compare IL-6 complex biomarkers in AA women with and without a history of BC. We conducted a secondary analysis of phenotypic data from two studies of weight loss in AA women with and without a history of BC who had similar age and adiposity. Biomarkers analyzed included tumor necrosis factor alpha (TNF-α), IL-6, IL-6 soluble receptor (IL6sr), and soluble glycoprotein 130 (GP130); IL6sr and GP130 were newly analyzed for this study. TNF-α levels were 1.86 times higher in the BC group (N = 7) compared to those without BC (N = 10; p < 0.001) despite similar age, weight, and body mass index. GP130 levels tended to be higher in women with BC; IL-6 and Il-6 sr were not different between groups. There was a strong correlation between GP130 and TNF-α (r = .638; p = .006) in the group overall. High TNF-α levels in the BC group and a strong correlation between GP130 and TNF-α in the overall group suggest the presence of IL-6 complex initiated TNF-α production. Further study is needed to evaluate IL-6 reduction through a variety of approaches, including weight loss and anti-IL-6 therapies, which may ultimately implicate the reduction of IL-6 complex associated BC-specific recurrence and mortality.

Entities:  

Keywords:  breast cancer; health care disparities; inflammation; obesity

Mesh:

Substances:

Year:  2020        PMID: 32748635      PMCID: PMC8264857          DOI: 10.1177/1099800420945787

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  21 in total

1.  Weight loss with mindful eating in African American women following treatment for breast cancer: a longitudinal study.

Authors:  SeonYoon Chung; Shijun Zhu; Erika Friedmann; Catherine Kelleher; Adriane Kozlovsky; Karen W Macfarlane; Katherine H R Tkaczuk; Alice S Ryan; Kathleen A Griffith
Journal:  Support Care Cancer       Date:  2015-10-13       Impact factor: 3.603

2.  Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Authors:  Elizabeth Barrett-Connor; Lori Mosca; Peter Collins; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Michelle A McNabb; Nanette K Wenger
Journal:  N Engl J Med       Date:  2006-07-13       Impact factor: 91.245

3.  Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.

Authors:  Xian-Peng Jiang; Ding Cheng Yang; Robert L Elliott; Jonathan F Head
Journal:  Anticancer Res       Date:  2011-09       Impact factor: 2.480

Review 4.  Small molecule inhibitors of Stat3 signaling pathway.

Authors:  Jinxia Deng; Fedora Grande; Nouri Neamati
Journal:  Curr Cancer Drug Targets       Date:  2007-02       Impact factor: 3.428

5.  IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma.

Authors:  I Garcia-Tuñón; M Ricote; A Ruiz; B Fraile; R Paniagua; M Royuela
Journal:  Histopathology       Date:  2005-07       Impact factor: 5.087

6.  Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study.

Authors:  Walter Gianni; Andrea Ricci; Paola Gazzaniga; Marina Brama; Maria Pietropaolo; Sergio Votano; Francesco Patanè; Anna Maria Aglianò; Giovanni Spera; Vincenzo Marigliano; Sergio Ammendola; Donato Agnusdei; Silvia Migliaccio; Roberto Scandurra
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  Identification of a protein factor secreted by 3T3-L1 preadipocytes inhibitory for the human MCF-7 breast cancer cell line.

Authors:  P G Johnston; C M Rondinone; D Voeller; C J Allegra
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

8.  Effects of a weight loss intervention on body mass, fitness, and inflammatory biomarkers in overweight or obese breast cancer survivors.

Authors:  Bilgé Pakiz; Shirley W Flatt; Wayne A Bardwell; Cheryl L Rock; Paul J Mills
Journal:  Int J Behav Med       Date:  2011-12

9.  Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation.

Authors:  Sachin K Deshmukh; Sanjeev K Srivastava; Arun Bhardwaj; Ajay P Singh; Nikhil Tyagi; Saravanakumar Marimuthu; Donna L Dyess; Valeria Dal Zotto; James E Carter; Seema Singh
Journal:  Oncotarget       Date:  2015-05-10

Review 10.  Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.

Authors:  Tae-Hwe Heo; Joseph Wahler; Nanjoo Suh
Journal:  Oncotarget       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.